AU2001268421A1 - Statement as to federally sponsored research - Google Patents

Statement as to federally sponsored research

Info

Publication number
AU2001268421A1
AU2001268421A1 AU2001268421A AU6842101A AU2001268421A1 AU 2001268421 A1 AU2001268421 A1 AU 2001268421A1 AU 2001268421 A AU2001268421 A AU 2001268421A AU 6842101 A AU6842101 A AU 6842101A AU 2001268421 A1 AU2001268421 A1 AU 2001268421A1
Authority
AU
Australia
Prior art keywords
antimicrobial
peptide
seq
isoleucine
novispirin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268421A
Other languages
English (en)
Inventor
Robert I Lehrer
Brian F. Tack
Alan J. Waring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
University of California
Original Assignee
University of Iowa Research Foundation UIRF
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/840,009 external-priority patent/US6492328B2/en
Application filed by University of Iowa Research Foundation UIRF, University of California filed Critical University of Iowa Research Foundation UIRF
Publication of AU2001268421A1 publication Critical patent/AU2001268421A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)
AU2001268421A 2000-06-28 2001-06-13 Statement as to federally sponsored research Abandoned AU2001268421A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60685800A 2000-06-28 2000-06-28
US09/606,858 2000-06-28
US09/840,009 US6492328B2 (en) 2000-06-28 2001-04-19 Novispirins: antimicrobial peptides
US09/840,009 2001-04-19
PCT/US2001/019094 WO2002000839A2 (fr) 2000-06-28 2001-06-13 Novispirines: peptides antimicrobiens

Publications (1)

Publication Number Publication Date
AU2001268421A1 true AU2001268421A1 (en) 2002-01-08

Family

ID=27085347

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268421A Abandoned AU2001268421A1 (en) 2000-06-28 2001-06-13 Statement as to federally sponsored research

Country Status (7)

Country Link
EP (1) EP1359930A4 (fr)
JP (1) JP2004526663A (fr)
AU (1) AU2001268421A1 (fr)
BR (1) BR0112035A (fr)
CA (1) CA2415236A1 (fr)
IL (1) IL153556A0 (fr)
WO (1) WO2002000839A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7071293B1 (en) * 1999-08-18 2006-07-04 The University Of Iowa Research Foundation Alpha helical peptides with broad spectrum antimicrobial activity that are insensitive to salt
DE60326226D1 (de) * 2002-03-21 2009-04-02 Cayman Chemical Co Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
WO2005092365A2 (fr) * 2004-03-29 2005-10-06 Novozymes A/S Utilisation pharmaceutique des novispirines
US7148404B2 (en) 2004-05-04 2006-12-12 Novozymes A/S Antimicrobial polypeptides
WO2008096814A1 (fr) * 2007-02-09 2008-08-14 Genomidea Inc. Nouveau polypeptide et agent antibactérien le renfermant en tant que principe actif
GB201115910D0 (en) 2011-09-14 2011-10-26 Univ Manchester Peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012668A1 (fr) * 1999-08-18 2001-02-22 University Of Iowa Research Foundation Peptides derives de la cathelicidine ayant une activite antimicrobienne a large spectre

Also Published As

Publication number Publication date
EP1359930A2 (fr) 2003-11-12
BR0112035A (pt) 2006-02-21
JP2004526663A (ja) 2004-09-02
EP1359930A4 (fr) 2004-07-14
WO2002000839A3 (fr) 2003-08-28
WO2002000839A2 (fr) 2002-01-03
IL153556A0 (en) 2003-07-06
CA2415236A1 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
US6492328B2 (en) Novispirins: antimicrobial peptides
JP5969457B2 (ja) 化合物およびそれらの使用
JP7315724B2 (ja) リシン置換を含むＲｏｍｏ１由来抗菌ペプチドおよびその変異体
AU2005288519A1 (en) Fatty acid modified polylysines as antimicrobial agents
Conlon et al. Clinical applications of amphibian antimicrobial peptides
OA10059A (en) Compositions and methods for treating infections caused by organisms sensitive to beta-lactam antibiotics
US20090203611A1 (en) Anti-microbial defensin-related peptides and methods of use
TW201028154A (en) Antibiotic synergism
US20060217306A1 (en) Systemic treatment of infections with defensins
AU2001268421A1 (en) Statement as to federally sponsored research
US20050245452A1 (en) Pharmaceutical use of novispirins
Conlon The potential of frog skin antimicrobial peptides for development into therapeutically valuable anti-infective agents
ZA200300374B (en) Novispirins: Antimicrobial peptides.
US20090253629A1 (en) Use of defensins against meningitis
US8653024B2 (en) Use of AMPs for treatment of UTI/cystitis
US20230181678A1 (en) Novel antibacterial peptide or peptide analog and use thereof
JPH04506056A (ja) ペプチド組合せ組成物及びその用法
US20090149391A1 (en) Novel antimicrobial bolisin peptides
US20110130326A1 (en) Defensins for treatment of infective endocarditis
PL166731B1 (pl) Sposób wytwarzania środka do leczenia infekcji wywołanych przez organizmy wrażliwe na antybiotykiβ-laktamowe
WO2005092365A2 (fr) Utilisation pharmaceutique des novispirines

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application